Regeneron doubles down on partner Adicet's gamma delta T cell tech in $80M financing
Three years after singling out Adicet Bio as a top contender in the race for a new wave of off-the-shelf immune cell therapies and putting down $25 million upfront for a research pact, Regeneron is reinforcing its endorsement in the form of an equity investment.
The big biotech has jumped into an $80 million Series B for its partner, which is designed to further its work on gamma delta T cells and push a lead therapy for non-Hodgkin’s lymphoma to the clinic. Solid tumor programs will follow.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 63,000+ biopharma pros reading Endpoints daily — and it's free.